Holen Sie sich die Stockscreener-App
30.84
6.64%
1.92
Vorhandelsmarkt:
33.17
2.33
+7.56%
Schlusskurs vom Vortag:
$28.92
Offen:
$28.59
24-Stunden-Volumen:
1.38M
Relative Volume:
1.20
Marktkapitalisierung:
$3.68B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-10.67
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
+14.01%
1M Leistung:
-3.08%
6M Leistung:
-31.65%
1J Leistung:
+203.54%
1-Tages-Spanne:
$28.59
$31.30
1-Wochen-Bereich:
$27.49
$31.30
52-Wochen-Spanne:
$9.93
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
30.84 | 3.68B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
FY2025 Earnings Estimate for RNA Issued By Cantor Fitzgerald - MarketBeat
Equities Analysts Set Expectations for RNA Q1 Earnings - MarketBeat
Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) - MarketBeat
Exciting News from Avidity Biosciences! New Opportunities Await! - Qhubo
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
Avidity Biosciences Awards New Employee Stock Options and RSUs Worth $304K - StockTitan
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential - Insider Monkey
Avidity Set To File First Of Three Muscular Dystrophy Drugs In 2025 - News & Insights
Avidity Biosciences Inc (RNA-Q) QuotePress Release - The Globe and Mail
Avidity Biosciences Becomes Oversold (RNA) - Nasdaq
Avidity Biosciences (NASDAQ:RNA) Sees Large Volume IncreaseHere's Why - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Given Buy Rating at HC Wainwright - MarketBeat
Analyst Expectations For Avidity Biosciences's Future - Benzinga
JPMorgan Chase & Co. Has $21.45 Million Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Avidity Biosciences, Inc. Announces 2025 Upcoming Clinical and Regulatory Highlights - Marketscreener.com
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 - PR Newswire
Principal Financial Group Inc. Reduces Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $64.36 Average Target Price from Analysts - MarketBeat
Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now? - Insider Monkey
Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth - Simply Wall St
12 Best Multibagger Stocks to Buy Right Now - Insider Monkey
Avidity Biosciences (NASDAQ:RNA) Trading Down 5.4%What's Next? - MarketBeat
Avidity Biosciences Joins Patient and Advocacy Communities in Ra - GuruFocus.com
Franklin Resources Inc. Acquires 50,908 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Chardan Capital Has Negative Outlook of RNA FY2024 Earnings - MarketBeat
Avidity Biosciences' CSTO Flanagan sells $416,153 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO sells $364,191 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CEO Sarah Boyce sells $1.04 million in stock - Investing.com India
Avidity Biosciences CHRO Teresa McCarthy sells $364,191 in stock By Investing.com - Investing.com Australia
Avidity Biosciences (NASDAQ:RNA) Shares Up 3.2%Still a Buy? - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Now Covered by Analysts at HC Wainwright - MarketBeat
Avidity Biosciences shares initiated with Buy on establishment By Investing.com - Investing.com UK
What 8 Analyst Ratings Have To Say About Avidity Biosciences - Benzinga
Avidity Biosciences CFO sells $364,191 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $1.04 million in stock By Investing.com - Investing.com South Africa
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 12,742 Shares of Stock - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells $1,040,384.30 in Stock - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 11,151 Shares - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $364,191 in stock - Investing.com
Avidity Biosciences' CSTO Flanagan sells $416,153 in stock - Investing.com India
Avidity Biosciences CHRO Teresa McCarthy sells $831,605 in stock By Investing.com - Investing.com Nigeria
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 25,000 Shares of Stock - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $831,605 in stock - Investing.com India
Geode Capital Management LLC Buys 328,606 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avidity Biosciences Inc-Aktie (RNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MacLean Michael F | Chief Financial Officer |
Dec 18 '24 |
Sale |
32.66 |
11,151 |
364,192 |
82,942 |
| Boyce Sarah | President and CEO |
Dec 18 '24 |
Sale |
32.66 |
31,855 |
1,040,384 |
265,308 |
| McCarthy Teresa | Chief Human Resources Officer |
Dec 18 '24 |
Sale |
32.66 |
11,151 |
364,192 |
82,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Dec 16 '24 |
Option Exercise |
14.22 |
25,000 |
355,500 |
119,018 |
| McCarthy Teresa | Chief Human Resources Officer |
Dec 16 '24 |
Sale |
33.26 |
25,000 |
831,605 |
94,018 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):